The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Open accessAbstract
Objective: To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer. Design: Scandinavian cohort study. Setting: Denmark, Norway, and Sweden, 2007-21. Participants: Patients who started GLP1 receptor agonist treatment were compared with patients who started dipeptidyl peptidase 4 (DPP4) inhibitor treatment, and in an additional analysis, patients who started sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment. Main outcome measures: Thyroid cancer identified from nationwide cancer registers. An active-comparator new user study design was used to minimise risks of confounding and time related biases from using real world studies of drug effects. Cox regression was used to estimate hazard ratios, controlling for potential confounders with propensity score weighting. Results: The mean follow-up time was 3.9 years (standard deviation 3.5 years) in the GLP1 receptor agonist group and 5.4 years (standard deviation 3.5 years) in the DPP4 inhibitor group. 76 of 145 410 patients (incidence rate 1.33 events per 10 000 person years) treated with GLP1 receptor agonists and 184 of 291 667 patients (incidence rate 1.46 events per 10 000 person years) treated with DPP4 inhibitors developed thyroid cancer. GLP1 receptor agonist use was not associated with increased risk of thyroid cancer (hazard ratio 0.93, 95% confidence interval 0.66 to 1.31; rate difference −0.13, 95% confidence interval −0.61 to 0.36 events per 10 000 person years). The hazard ratio for medullary thyroid cancer was 1.19 (0.37 to 3.86). In the additional analysis comparing the GLP1 receptor agonist group with the SGLT2 inhibitor group, the hazard ratio for thyroid cancer was 1.16 (0.65 to 2.05). Conclusions: In this large cohort study using nationwide data from three countries, GLP1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years. In the main analysis comparing GLP1 receptor agonists with DPP4 inhibitors, the upper limit of the confidence interval was consistent with no more than a 31% increase in relative risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, while murine studies initially raised concerns about thyroid C-cell tumors,71 current human data do not suggest an increased risk.72,73”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent Scandinavian real‐world study 106 found no increased risk of thyroid cancer among initiators of GLP‐1RA vs. dipeptidyl‐peptidase 4 inhibitors (DPP4i).”
From Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies (2025) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“a Scandinavian cohort study using nationwide cancer registries found no association between GLP-1RA use and thyroid cancer (HR 0.93, 95 % CI 0.66–1.31) (80).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marginal Structural Models and Causal Inference in Epidemiology
Robins, J. M., Hernán, M. Á., & Brumback, B. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00011 · Cited by 5,581
Hernán, M. Á., Brumback, B., & Robins, J. M. (2000) · Epidemiology · doi:10.1097/00001648-200009000-00012 · Cited by 1,782
The changing incidence of thyroid cancer
Kitahara, C. M., & Sosa, J. A. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.110 · Cited by 1,051
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
An Empirical Transition Matrix for Non-homogeneous Markov Chains Based on Censored Observations
Johansen, R. (1978) · Cited by 844
Lund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 1×
“The study design was an active-comparator new user design, 11 with DPP4 inhibitors as the comparator.”
Nordic Cancer Registries – an overview of their procedures and data comparability
Pukkala, E., Engholm, G., Højsgaard Schmidt, L. K., Storm, H., Khan, S., Lambe, M., Pettersson, D., Ólafsdóttir, E., Tryggvadóttir, L., Hakanen, T., et al. (2018) · Acta Oncologica · doi:10.1080/0284186x.2017.1407039 · Cited by 347
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Parks, M., & Rosebraugh, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1001578 · Cited by 275
Desai, R. J., Rothman, K. J., Bateman, B. T., Hernandez-Diaz, S., & Huybrechts, K. F. (2017) · Epidemiology · doi:10.1097/ede.0000000000000595 · Cited by 245
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Baxter, S. M., Lund, L. C., Andersen, J. H., Brix, T. H., Hegedüs, L., Hsieh, M. H.-C., Su, C. T.-T., Cheng, M. C.-Y., Chang, Z. C.-J., Lai, E. C.-C., et al. (2025) · Thyroid® · doi:10.1089/thy.2024.0387 · Cited by 81
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 76
Obesity-driven inflammation and cancer risk: A comprehensive review
Lamabadusuriya, D. A., Jayasena, H., Bopitiya, A. K., Silva, A. D. D., & Jayasekera, P. T. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.07.007 · Cited by 76
Metadata
- Authors
- Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P.
- Affiliations
- Statens Serum Institut (DK)
- Karolinska Institutet (SE)
- Sahlgrenska University Hospital (SE)
- The Swedish National Diabetes Register, Västra Götalandsregionen, Gothenburg, Sweden
- Norwegian University of Science and Technology (NO)
- University of Copenhagen (DK)
- Corresponding author
- Pasternak, Björn
- ORCID
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2024-04-10
- Volume
- 385
- Pages
- e078225
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC11004669
- OpenAlex
- W4394707684
- Cited by
- 125
- References
- 24
- Citations by year
- 2026: 47 · 2025: 58 · 2024: 20
- FWCI
- 41.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BMJ (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Vetenskapsrådet
- Karolinska Institutet
- Novo Nordisk Fonden
- Cancerfonden
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- GLP-1 receptor agonists, thyroid cancer, medullary thyroid carcinoma, DPP-4 inhibitors, SGLT2 inhibitors, drug safety, cancer risk, type 2 diabetes treatment, propensity score weighting
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Aged, Denmark, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Norway, Risk Factors, Scandinavian and Nordic Countries, Sweden, Thyroid Neoplasms, Cohort Studies, Incidence, Proportional Hazards Models, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. https://app.cochat.ai/papers/10.1136/bmj-2023-078225
- The paper
- Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024). Glucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. https://doi.org/10.1136/bmj-2023-078225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.